High Blood Pressure (Hypertention)
- Bayer Indonesia
- Transfers of Value to Healthcare Professionals
Hypertension is called the “Silent Killer” since most patients with high blood pressure have no symptoms to alert them to the elevated pressure. But over time, high blood pressure increases the risk of serious problems such as stroke, heart failure, and kidney failure.
In 2000, there are approximately 26% of the world population, or equal to 972 million people, that suffer from hypertension, and its prevalence is predicted to increase to 29% by 20251. In Indonesia, hypertension prevalence in 2018 was 34.1%, based on the measurement to the population with the age of ≥ 18 years old. Estimated number of hypertension case in Indonesia is 63,309,620 people, with the mortality number of 427,218 deaths. The percentage breakdown of hypertension by age is 31 - 44 years old (31.6%), 45 - 54 years old (45.3%), and 55 - 64 years old (55.2%)2.
To control hypertension in order to achieve targeted blood pressure, the work begins with lifestyle changes, which is maintaining healthy lifestyle, ideal weight, and reducing consumption of salt. Patients compliance in treatment, correct and regular blood pressure measurement, are crucial in controlling hypertension.
According to the Consensus of Hypertension Treatment Management 2019, for patients with blood pressure ≥ 140 mmHg / ≥ 90 mmHg, medicine will need to be administered to lower blood pressure.
The main objective of hypertension management is to achieve maximum reduction of morbidity and mortality.
In Indonesia, all types of medicines to control blood pressure are available, namely : Calcium Channel Blocker (CCB), Diuretic, Beta Blocker, Alpha Blocker, Anti Converting Enzyme Inhibitor (ACE inhibitor), Angiotensinogen Receptor Blocker (ARB), Aldosteron Antagonist and others. Currently, according to the InaSH guidelines 2019, use of anti- hypertension drug is recommended to be combined since the beginning of the treatment, hence targeted blood pressure can be achieved and maintain blood pressure stability for 24 hours.
Many studies using reliable methods have been carried out to ensure the potency, safety and tolerability of anti-hypertension medicines. For example, the use of Calcium Channel Blocker type, in this case is Nifedipine with OROS technology, be it as a single medication or combined with other anti-hypertension medicine, is able to deliver effective and safe treatment of hypertension that is proven to be tolerable through the daily medication practice, in a wide spectrum among hypertension patients3.
Nifedipine with OROS technology is Nifedipine using Osmotic-controlled Release Oral delivery System technology, OROS, which allows Nifedipine to stay in the body for 24 hours and maintain normal blood pressure throughout the day.
1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Lancet. 2005 Jan 15- 21;365(9455):217-23.
2. Riset Kesehatan Dasar (National Health Survey) 2018
3. https://www.ncbi.nlm.nih.gov/pubmed/21591 818
Advice for patients : Each body reacts differently to medicines. Therefore, it is impossible to tell which medicine works best for you. Please consult your physician.